European regulators recommend rejection of Merck’s Covid-19 drug molnupiravir
European regulators recommended the EMA reject Merck’s Covid antiviral, saying that there’s not enough evidence it works in patients.
Merck and partner Ridgeback Biotherapeutics announced the CHMP’s decision on Friday.
The committee refused to recommend the approval of Lagevrio, also known as molnupiravir, by initially stating that the review has been ongoing for more than a year. The committee had supported decisions from member states starting in November 2021, if they wanted to consider early use of molnupiravir before any potential approval.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.